Katie L Thoren1, Matthew J Pianko2, Youssef Maakaroun3, C Ola Landgren2, Lakshmi V Ramanathan4. 1. Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; thorenk@mskcc.org. 2. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Sebia Inc., Norcross, GA. 4. Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
BACKGROUND: Daratumumab, a monoclonal antibody used to treat relapsed or refractory multiple myeloma, can interfere with protein electrophoresis and immunofixation assays. False-positive immunofixation results due to daratumumab can cause uncertainty regarding the status of a patient's disease and lead to potential misclassification of their response to therapy. The Hydrashift 2/4 Daratumumab assay (Sebia) was recently cleared by the Food and Drug Administration for resolving daratumumab interference on immunofixation. Here, we evaluate the performance of the Hydrashift assay in multiple myeloma patients receiving treatment with daratumumab-based regimens. METHODS: Waste serum samples from multiple myeloma patients (n = 40) receiving daratumumab were analyzed by standard immunofixation and the Hydrashift assay. Results from these tests were compared and were evaluated along with pretreatment serum protein electrophoresis and immunofixation results, if available. RESULTS: The Hydrashift assay shifted the migration of daratumumab in patient samples. In 27 cases, the patient's M protein was distinguishable from daratumumab by standard immunofixation. In these cases, the Hydrashift assay confirmed that the IgGκ band was daratumumab and helped identify the presence of treatment-related oligoclonal bands. There were 11 instances in which the patient's IgGκ M protein comigrated with daratumumab. In all 11 cases, the Hydrashift assay confirmed the presence of residual M protein. Finally, in 2 patients whose pretreatment immunofixation results were not available, the Hydrashift assay confirmed that the IgGκ band visible on immunofixation was due to daratumumab alone. CONCLUSIONS: The Hydrashift 2/4 Daratumumab assay is a useful tool to clarify the source of an IgGκ band on immunofixation and allow a patient's M protein to be viewed without interference.
BACKGROUND:Daratumumab, a monoclonal antibody used to treat relapsed or refractory multiple myeloma, can interfere with protein electrophoresis and immunofixation assays. False-positive immunofixation results due to daratumumab can cause uncertainty regarding the status of a patient's disease and lead to potential misclassification of their response to therapy. The Hydrashift 2/4 Daratumumab assay (Sebia) was recently cleared by the Food and Drug Administration for resolving daratumumab interference on immunofixation. Here, we evaluate the performance of the Hydrashift assay in multiple myelomapatients receiving treatment with daratumumab-based regimens. METHODS: Waste serum samples from multiple myelomapatients (n = 40) receiving daratumumab were analyzed by standard immunofixation and the Hydrashift assay. Results from these tests were compared and were evaluated along with pretreatment serum protein electrophoresis and immunofixation results, if available. RESULTS: The Hydrashift assay shifted the migration of daratumumab in patient samples. In 27 cases, the patient's M protein was distinguishable from daratumumab by standard immunofixation. In these cases, the Hydrashift assay confirmed that the IgGκ band was daratumumab and helped identify the presence of treatment-related oligoclonal bands. There were 11 instances in which the patient's IgGκ M protein comigrated with daratumumab. In all 11 cases, the Hydrashift assay confirmed the presence of residual M protein. Finally, in 2 patients whose pretreatment immunofixation results were not available, the Hydrashift assay confirmed that the IgGκ band visible on immunofixation was due to daratumumab alone. CONCLUSIONS: The Hydrashift 2/4 Daratumumab assay is a useful tool to clarify the source of an IgGκ band on immunofixation and allow a patient's M protein to be viewed without interference.
Authors: Christopher R McCudden; Peter M Voorhees; Shirley A Hainsworth; Herbert C Whinna; John F Chapman; Catherine A Hammett-Stabler; Monte S Willis Journal: Clin Chem Date: 2010-10-12 Impact factor: 8.327
Authors: Christopher R McCudden; Joannes F M Jacobs; David Keren; Hélène Caillon; Thomas Dejoie; Kristian Andersen Journal: Clin Biochem Date: 2017-08-24 Impact factor: 3.281
Authors: María-Victoria Mateos; Meletios A Dimopoulos; Michele Cavo; Kenshi Suzuki; Andrzej Jakubowiak; Stefan Knop; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Polina Kaplan; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna M Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Iosava; Tomoaki Fujisaki; Mamta Garg; Christopher Chiu; Jianping Wang; Robin Carson; Wendy Crist; William Deraedt; Huong Nguyen; Ming Qi; Jesus San-Miguel Journal: N Engl J Med Date: 2017-12-12 Impact factor: 91.245
Authors: Kazunori Murata; Samuel I McCash; Brittany Carroll; Alexander M Lesokhin; Hani Hassoun; Nikoletta Lendvai; Neha S Korde; Sham Mailankody; Heather J Landau; Guenther Koehne; David J Chung; Sergio A Giralt; Lakshmi V Ramanathan; Ola Landgren Journal: Clin Biochem Date: 2016-09-21 Impact factor: 3.281
Authors: John R Mills; Mindy C Kohlhagen; Surendra Dasari; Patrick M Vanderboom; Robert A Kyle; Jerry A Katzmann; Maria A V Willrich; David R Barnidge; Angela Dispenzieri; David L Murray Journal: Clin Chem Date: 2016-08-18 Impact factor: 8.327
Authors: Christopher McCudden; Amy E Axel; Dominique Slaets; Thomas Dejoie; Pamela L Clemens; Sandy Frans; Jaime Bald; Torben Plesner; Joannes F M Jacobs; Niels W C J van de Donk; Philippe Moreau; Jordan M Schecter; Tahamtan Ahmadi; A Kate Sasser Journal: Clin Chem Lab Med Date: 2016-06-01 Impact factor: 3.694
Authors: Niels W C J van de Donk; Henny G Otten; Omar El Haddad; Amy Axel; A Kate Sasser; Sandra Croockewit; Joannes F M Jacobs Journal: Clin Chem Lab Med Date: 2016-06-01 Impact factor: 3.694
Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316
Authors: Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751
Authors: Paolo Milani; Marco Basset; Mario Nuvolone; Francesca Benigna; Lara Rodigari; Francesca Lavatelli; Andrea Foli; Giampaolo Merlini; Giovanni Palladini Journal: Blood Cancer J Date: 2020-09-01 Impact factor: 11.037